Industry Trends, Expansion Technologies, Profiles of Selected Cord Blood Banks and Companies

DUBLIN, January 13, 2021 / PRNewswire / – The “Global Cord Blood Banking Industry Report 2021” the report was added to ResearchAndMarkets.com offer.

From the early 1900s to the mid-2000s, the global cord blood banking industry proliferated with the emergence of cord blood banks in all major healthcare markets around the world. From 2005 to 2010, the market reached saturation and stabilized. From 2010 to 2020, the market began to consolidate aggressively, creating both threats and opportunities within the industry.

Serious threats to the industry include low rates of use of stored cord blood, expensive cord blood transplant procedures, difficulty in educating obstetricians about cell therapy, and a growing trend towards consolidation. industry. Opportunities for the industry include cost savings associated with scale and consolidation, accelerated regulatory pathways for cord blood and tissue-based cell therapies, and advancements with ex vivo cell expansion technologies.

Cord blood industry trends

In recent years, new themes have impacted the industry, including the combination of stem cell storage services with genetic and genomic testing services, as well as reproductive health services. Cord blood banks are diversifying into new types of stem cell storage, including storage of umbilical cord tissue, blood and placental tissue, amniotic fluid and tissue, and dental pulp. Cord blood banks are also exploring ways to become integrated therapy businesses. With hundreds of companies offering cord blood banking services around the world, the maturing of the market means that each company is fighting harder for its market share.

More and more investors are also entering the market, with mergers and acquisitions accelerating in the United States and abroad. Holding companies are emerging as a global theme, enabling increased operational efficiency and economies of scale. Cryoholdco has established itself as the market leader within Latin America. Created in 2015, Cryoholdco is a holding company that controls more than a quarter of a million units of stem cells (around 270,000). She owns half a dozen cord blood banks, as well as a dental stem cell storage company.

Globally, cord blood banking networks have become commonplace, with the Sanpower Group establishing its dominance in Asia. Although Sanpower has been silent on its operations, it holds 4 licenses out of just 7 cord blood bank licenses issued at the provincial level in China. It has reserved more than 900,000 cord blood samples in China, and its reserves stand at over 1.2 million units when Cordlife reserves in Southeast Asian countries are included. This positions the Sanpower group and its subsidiary Nanjing Cenbest as the world’s largest operator of cord blood banking not only in China and South East Asia but in the world.

The number of cord blood banks Europe has fallen by more than a third over the past decade, from around 150 to less than 100. Industry leaders in this market segment include FamiCord Group, which has executed a dozen merger deals and acquisitions, and Vita34, which executed about half a dozen transactions. Stemlab, the world’s largest cord blood bank Portugal, also completed three acquisition transactions before being acquired by FamiCord. FamiCord is now the first stem cell bank in Europe and one of the most important in the world.

Cord blood expansion technologies

Since the use of cord blood is largely limited to pediatric patients, increasing investments are being made in ex vivocord blood expansion technologies. If successful, this technology could dramatically expand the potential of the cord blood market, encouraging its use in new markets, such as regenerative medicine, aging and enhanced immunity.

Currently, Gamida Cell, Nohla Therapeutics, Excellthera and Magenta Therapeutics have ex vivo cord blood expansion products in clinical trials. A growing number of investors have also entered the cord blood banking market, led by groups such as GI Partners, ABS Capital Partners & HLM Management, KKR & Company, Bay City Capital, GTCR, LLC and Excalibur.

The key questions answered in this report are:

  1. What strategies are being considered to improve the financial stability of public cord blood banks?
  2. What companion products are offered to be developed from cord blood?
  3. How much do you spend on processing and storing a unit of cord blood?
  4. How much does a unit of cryopreserved cord blood cost when it is released?
  5. Why do most public cord blood banks suffer a loss?
  6. What is the net profit margin of a private cord blood bank?
  7. What are the costs of processing and storing cord blood in private cord blood banks?
  8. What are the rates per unit of cord blood in the United States and Europe?
  9. What are the revenues from cord blood sales for the major cord blood banks?
  10. What are the different accreditation systems for cord blood banks?
  11. What are the comparative advantages of various cord blood processing technologies?
  12. What can be done to increase the rate of use of cord blood cells in transplants?
  13. What numbers of TNCs are preferred for transplantation?
  14. What is the number of registered clinical trials using blood and cord tissue?
  15. How many clinical trials are involved in studying the expansion of cord blood cells in the laboratory?
  16. How many match and mismatch transplants using cord blood units are performed each year?
  17. What is the share of cord blood cells used for transplantation from 2000 to 2020?
  18. What is the probability of finding a matching allogeneic cord blood unit by ethnicity?
  19. What are the top ten countries for cord blood donation?
  20. What are the diseases targeted by MSCs derived from cord blood in clinical trials?

Profiles of some cord blood banks and companies

  • All cells
  • AlphaCord LLC
  • Amecord Registry, Inc.
  • Be the match
  • Biocell Center Company
  • BioEden Group, Inc.
  • Biovault family
  • Cellular care
  • Cell-Save
  • Cells4Life Group, LLP
  • International Center for Research on Blood and Marrow Transplants (CIBMTR)
  • Group of cord blood centers
  • Cord blood registry (CBR)
  • Cordlife Group, Ltd.
  • CordVida
  • Core23 Biobank
  • Crio-Cell International, Inc.
  • Crioestaminal
  • Cryo-Cell International, Inc.
  • CryoHoldco
  • Cryoviva Biotech Pvt. Ltd.
  • European Society for Blood and Bone Marrow Transplantation (EBMT)
  • FamiCord Group
  • GeneCell International
  • World Cord Blood Society
  • HealthBaby Hong Kong
  • HEMA FUNDS
  • Inception Life Bank
  • Lifebank United States
  • LifeCell International Pvt. Ltd.
  • Labyrinth Cord Blood Laboratories
  • MiracleCord, Inc.
  • New England Cord Blood Bank, Inc.
  • New York Cord Blood Center (NYBC)
  • PacifiCord
  • ReeLabs Pvt. Ltd.
  • Smart Cells International, Ltd.
  • Cryobank of stem cells
  • StemCyte, Inc.
  • Transcell Biolife
  • ViaCord
  • Vita 34 AG
  • World Association of Marrow Donors (WMDA)
  • Global Blood and Marrow Transplantation Network (WBMT)

For more information on this report, visit https://www.researchandmarkets.com/r/amvb5q

Research and Markets also offers Custom Search services providing targeted, comprehensive and appropriate research.

Media contact:

Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1907
Fax (outside the United States): + 353-1-481-1716

SOURCE Research and Markets

Related links

http://www.researchandmarkets.com


Source link

About the author